
Celularity Investor Relations Material
Latest events

Analyst Research & Development Day 2024
Celularity

Q2 2025
29 Aug, 2025

Q1 2025
29 Aug, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Celularity Inc
Access all reports
Celularity Inc. is a biotechnology company focused on developing off-the-shelf, placental-derived allogeneic cell therapies for treating cancer, immune, and infectious diseases. The company's core therapeutic products include genetically modified and unmodified natural killer (NK) cells, CAR-T cells, and mesenchymal-like adherent stromal cells. Additionally, Celularity produces placental-derived biomaterials used in various therapeutic applications. It operates through three main segments: Cell Therapy, Degenerative Disease, and BioBanking. The company is headquartered in Florham Park, New Jersey, and its shares are listed on NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
CELU
Country
🇺🇸 United States